Galapagos, Boehringer Ingelheim, ProStrakan, Novartis deal

GLPG received a $1 million milestone payment from NVS under a September deal between the pharma and ProSkelia S.A., which GLPG acquired from PSK last year (see BioCentury, Jan. 1). GLPG will pay $750,000 of the milestone to PSK. The deal gave NVS rights to research, develop and commercialize its preclinical MAbs against an undisclosed PSK target to treat bone-related diseases (see BioCentury, Oct. 2, 2006). The payment was triggered by an undisclosed event. ...